|
Market Cap (4-Jul) $356,619,552 (530th) |
Close (30-Jun) $0.315 |
Volume (30-Jun) 2,012,212 |
Shortsold (19-Jun) 27,150,697 (1.86%) (138th) |
|
52w High $0.415 |
52w Low $0.223 |
P/E 7.50 |
EPS -0.03 |
IMM released this announcement to the ASX on 27 January 2021, 8:59. The announcement is marked as price sensitive, and is 2 page(s) in length and 253.86kb in size.
You can view all announcements from IMM and see how they appear on a price chart on the announcements page.
At the date of this announcement, IMM was 0.050% short sold according to ASIC data. It was ranked the 465th most shorted stock on the ASX. It is now ranked as the 138th most shorted stock on the ASX with 1.859% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from IMM | |
|---|---|
| Application for quotation of securities - IMM | 29 June 2023, 10:09 |
| US patent granted for Efti with PD-1 pathway inhibitor | 27 June 2023, 14:37 |
| Immutep completes underwritten retail entitlement offer | 27 June 2023, 8:16 |
| Phase II study for eftilagimod alpha in COVID-19 advances | 27 January 2021, 8:59 |
| Immutep Quarterly Activities Report & Appendix 4C | 22 January 2021, 8:57 |
| Ulcerative Colitis Phase II Study of GSK2831781 Discontinued | 22 January 2021, 8:54 |
| Recruitment of head & neck cancer patients completed for ph2 | 7 January 2021, 9:33 |
You must be logged in to post a reply.
